Ashwagandha has spent the last few years as one of the most popular herbal supplements in the world, taken for stress, sleep, and general vitality. But 2025 and 2026 have also brought a wave of regulatory scrutiny that's changed how people talk about it. If you've seen headlines mentioning "FDA," "safety hearing," or "ashwagandha ban," here's what's actually happening, and what isn't.
Is There Really an FDA Hearing on Ashwagandha?
Not in the way a lot of social media posts suggest. There's no formal US FDA hearing specifically targeting ashwagandha safety at this time. What's true, and has been true for a while, is that the FDA has never formally reviewed ashwagandha for safety or effectiveness, and it isn't an FDA approved product, the same position it holds for most herbal dietary supplements sold in the US. Supplements in America are regulated differently from drugs: the FDA generally doesn't pre-approve them, it acts after safety concerns emerge.
The real regulatory pressure right now is coming from elsewhere:
Europe
Several European regulators have already acted. Ashwagandha has been banned or flagged with safety concerns by regulators in Denmark, the Netherlands, France, Belgium, Germany, and Poland. Denmark banned ashwagandha in food supplements back in 2023, while Dutch, French, German, and Swedish authorities advised consumers against its use around the same time. Germany's risk assessment body had already raised concerns years earlier, recommending against ashwagandha's use in food supplements due to worries about its effects on the endocrine system and its safety during pregnancy.
The debate isn't one-sided, though. Industry groups have pushed back hard. A mid-2026 industry gathering in Europe, organized around a "Safeguard Ashwagandha" initiative, argued the herb has strong supporting safety data and that regulators haven't fully weighed its benefits against the risks. One reviewer presenting at that meeting said his safety analysis held up even after applying a standard hundredfold safety margin, and pointed to research supporting around a dozen benefits, with the strongest evidence backing its use for sleep.
United Kingdom
The UK's Food Standards Agency opened a public consultation on ashwagandha safety in mid-2024. That call for evidence ran from July through early September of that year and was meant to gather data on toxicology, safety, and the scientific basis behind ashwagandha's marketed claims. As of the most recent updates, the FSA still hasn't published a final outcome or policy decision.
India
The most active recent developments have actually come out of India. Regulators there moved to restrict ashwagandha leaf extracts specifically, not the root. India's food safety authority issued an advisory banning ashwagandha leaf extracts in health supplements in April 2026, a decision that was quickly challenged by industry groups. A regional high court issued an interim stay on that ban after petitioners argued it bypassed formal regulatory procedures, and the case has continued through further hearings since.
Why the Safety Concerns Exist in the First Place
The core issue regulators keep coming back to is liver safety and hormone effects, not a sudden new discovery, but an ongoing conversation that started picking up steam a few years ago. Reports of liver-related side effects, along with older concerns about ashwagandha's traditional use affecting thyroid and reproductive hormones, are what pushed several European bodies to act first. Ashwagandha extracts do appear to help with stress, anxiety, and sleep, but evidence for many of its other marketed benefits is still limited, and most supporting studies are small and relatively short-term. It seems to be reasonably safe for short-term use, generally up to around 12 weeks, but its long-term safety hasn't been well established.
None of this means ashwagandha is inherently dangerous for everyone. It means the evidence for long-term daily use, and for certain populations like pregnant women, is thinner than the supplement's popularity would suggest.
What This Means for Everyday Supplement Users
A few practical takeaways from where things currently stand:
- Short-term use has the strongest safety and evidence base. Most of the positive research is built around a few weeks to a few months of use, not indefinite daily supplementation.
- Pregnancy and thyroid conditions are the biggest red flags. Several regulators cite these specifically, so anyone in either category should talk to a doctor before starting ashwagandha.
- "Not FDA approved" doesn't mean banned. In the US, ashwagandha remains legally available. The FDA simply hasn't formally reviewed it, which is normal for most herbal supplements, not a unique red flag.
- Root-only extracts appear to carry fewer concerns than leaf extracts, based on how regulators in India specifically targeted leaf-based formulations.
- Third-party testing matters more than ever. With this much regulatory back-and-forth, buying from a brand that can show real lab results is a much safer bet than trusting a label alone.
The Bigger Picture: Herbal Supplements Under More Scrutiny
Ashwagandha isn't an isolated case. It's part of a broader pattern where popular adaptogenic and traditional herbs are getting more regulatory attention as their global sales grow. That's not necessarily a bad thing for consumers. More scrutiny generally means more pressure on brands to actually prove what they're selling, rather than relying on vague "natural" marketing.
This is also exactly why sourcing and testing matter so much across the herbal supplement space generally, not just for ashwagandha. The same due diligence applies just as much when people look to buy Shilajit, another traditional mineral resin supplement that's seen a wave of counterfeit and low-quality products flood the market as demand has grown. Brands like Chitral House, a Pakistani producer known for direct sourcing from the Chitral region and third-party lab testing, are the kind of standard worth looking for, whether you're buying ashwagandha, Shilajit, or any other herbal product going through this level of global scrutiny. Checking for batch numbers, heavy metal testing, and transparent sourcing isn't optional anymore, it's the difference between an effective product and an expensive placebo.
Frequently Asked Questions
Has the FDA banned ashwagandha?
No. The FDA hasn't approved or formally reviewed ashwagandha, but it also hasn't banned it. It remains legally sold as a dietary supplement in the US.
Which countries have restricted ashwagandha?
Denmark has banned it in food supplements, while the Netherlands, France, Germany, Belgium, Poland, and Sweden have issued warnings or restrictions. India has restricted leaf extracts specifically, and the UK is still reviewing the evidence through its FSA consultation.
Is ashwagandha safe to take daily?
Short-term use, generally up to around 12 weeks, has the best safety data. Long-term daily use hasn't been studied as thoroughly, which is part of why regulators are being cautious.
Why are some countries banning ashwagandha leaf but not root?
Concerns have centered more on leaf extracts, which is why India's restriction specifically targeted leaf-based formulations rather than root extracts, the more traditionally used part of the plant.
Should I stop taking ashwagandha because of these reports?
Not necessarily, but it's worth discussing with a doctor, especially if you're pregnant, have a thyroid condition, or plan to use it long-term rather than in short cycles.
Does this affect other herbal supplements like Shilajit?
Not directly, Shilajit and ashwagandha are regulated separately and face different safety questions. But the broader lesson applies to both: buy from sellers who can show real lab testing rather than relying on marketing claims alone.
Conclusion
The ashwagandha story right now isn't a single dramatic US FDA hearing, it's a slower, more fragmented set of regulatory reviews happening across Europe, the UK, and India, driven by real questions about liver safety, hormone effects, and long-term use. None of that means the herb is unsafe for everyone, but it does mean the days of treating ashwagandha as a risk-free wellness trend are over. The same logic that applies here, buy tested, transparently sourced products from brands willing to prove their claims, is worth applying across the board, whether that's ashwagandha, or when you're looking to buy Shilajit from a producer like Chitral House.